Posts

Showing posts from July, 2021

Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome

  GATA2 deficiency is a heterogeneous multi-system disorder characterized by a high risk of developing myelodysplastic syndrome (MDS) and myeloid leukemia. We analyzed the outcome of 65 patients reported to the registry of the European Working Group (EWOG) of MDS in childhood carrying a germline  GATA2  mutation ( GATA2 mut ) who had undergone hematopoietic stem cell transplantation (HSCT). At 5 years the probability of overall survival and disease-free survival (DFS) was 75% and 70%, respectively. Non-relapse mortality and relapse equally contributed to treatment failure. There was no evidence of increased incidence of graft-versus-host-disease or excessive rates of infections or organ toxicities. Advanced disease and monosomy 7 (−7) were associated with worse outcome. Patients with refractory cytopenia of childhood (RCC) and normal karyotype showed an excellent outcome (DFS 90%) compared to RCC and −7 (DFS 67%). Comparing outcome of  GATA2 mut  with  GATA2 wt  patients, there was no

Paediatrics

 Paediatrics is a medical discipline focused on individuals from birth to the end of adolescence. The care of paediatric patients is different to that of adults, as many drugs are processed differently in these two groups. Growth and development are also more important in paediatric patients than in adults.